Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on May 30, 2023. The Company is incorporated in Nevada and maintains its principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The Nasdaq Stock Market under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes and Events
The primary event reported is the resolution of a listing deficiency with the Nasdaq Stock Market:
- Previous Status: On June 3, 2022, the Company received notification of non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
- Resolution: On May 30, 2023, Nasdaq notified the Company that it has regained compliance.
- Criteria Met: The closing bid price of the Company's common stock was at least $1.00 per share for 10 consecutive business days from May 15, 2023, through May 26, 2023.
- Current Status: The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No new risks or contingencies were disclosed in this specific report, other than the historical context of the prior listing deficiency which has now been resolved.
Investor Verification Checklist
- Verify the current trading price of XBIO to ensure continued compliance with Nasdaq minimum bid price rules.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Confirm the status of the Purchase Warrants (XBIOW) and any upcoming expiration dates.